# Pre-Submission Meeting Request -- PMA Pathway
## {device_description_short} -- Product Code {product_code}

**Date:** {generated_date}
**Requested Meeting Type:** {meeting_type} (PMA Pre-Submission)
**Product Code:** {product_code} -- {classification_device_name}
**Classification:** Class {device_class}, 21 CFR {regulation_number}
**Review Panel:** {review_panel}
**Regulatory Pathway:** Premarket Approval (PMA)
**Generated:** {generated_date} | FDA Tools Plugin v5.28.0

---

## 1. Cover Letter

{cover_letter_date}

{review_division_name}
{office_name}
Center for Devices and Radiological Health
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993

**RE: Pre-Submission Meeting Request -- PMA Pathway -- {device_trade_name}**

Dear Reviewer:

{applicant_name} respectfully requests a **{meeting_type} Pre-Submission meeting** with FDA to discuss the regulatory strategy and clinical development plan for our {device_description_short}. We believe this device is classified under product code **{product_code}** (21 CFR {regulation_number}, Class {device_class}).

We are pursuing the **Premarket Approval (PMA)** pathway and are seeking FDA's feedback on the following topics before finalizing our clinical study design and PMA submission strategy:

{question_summary_list}

We propose a **{meeting_format}** meeting format at FDA's earliest convenience. Our team, including clinical and statistical experts, is available for a meeting within the next 60 days.

Sincerely,

{contact_first_name} {contact_last_name}
{contact_title}
{applicant_name}
{contact_email}
{contact_phone}

---

## 2. Device Description

### 2.1 Overview

{device_description}

{device_trade_name} is {device_type_category} intended for {primary_use_summary}.

**Key Features:**
- {feature_1}
- {feature_2}
- {feature_3}

### 2.2 Principle of Operation

{principle_of_operation}

[TODO: Company-specific -- Detailed mechanism of action, therapeutic or diagnostic principle, and clinical rationale]

### 2.3 Key Components and Materials

**Components:**
{components_list}

**Materials in Patient Contact:**
{materials_list}

### 2.4 Physical Specifications

- **Dimensions:** {dimensions}
- **Weight:** {weight}
- **Sterilization:** {sterilization_method}
- **Shelf Life:** {shelf_life_claim}

### 2.5 Device Illustrations

[TODO: Company-specific -- Include device photographs, diagrams, cross-sections, and clinical use illustrations]

---

## 3. Proposed Indications for Use

**Device Trade Name:** {device_trade_name}

**Indications for Use:**

{intended_use}

**Prescription Use:** {rx_otc}

**Target Patient Population:**

[TODO: Company-specific -- Define specific patient population, including age, condition severity, and anatomical considerations]

---

## 4. PMA Regulatory Strategy

### 4.1 Pathway Justification

We are pursuing a **Premarket Approval (PMA)** for this device because:

{pathway_rationale}

[TODO: Company-specific -- Explain why PMA is required: Class III device, no legally marketed predicate, or novel intended use requiring clinical evidence of safety and effectiveness]

### 4.2 Comparable Approved Devices

[TODO: Company-specific -- List PMA-approved devices in this category as reference devices (not predicates). Include PMA numbers, approval dates, and clinical study designs used.]

| # | PMA Number | Device Name | Approval Date | Clinical Study Type |
|---|-----------|-------------|---------------|---------------------|
| 1 | [TODO] | [TODO] | [TODO] | [TODO] |
| 2 | [TODO] | [TODO] | [TODO] | [TODO] |

### 4.3 Regulatory Precedent Analysis

[TODO: Company-specific -- Analysis of how similar PMAs were approved, including clinical endpoints, sample sizes, and review timelines]

---

## 5. Questions for FDA

{auto_generated_questions}

---

## 6. Proposed Clinical Study Design

### 6.1 Study Overview

**Study Type:** [TODO: Company-specific -- Randomized controlled trial, single-arm study with OPC, etc.]

**Comparator/Control:** [TODO: Company-specific -- Active control, sham control, standard of care, objective performance criterion]

**Primary Objective:** [TODO: Company-specific -- Primary objective tied to safety and effectiveness endpoints]

### 6.2 Study Endpoints

**Primary Effectiveness Endpoint:**

[TODO: Company-specific -- Define primary endpoint with clinical relevance and measurability]

**Primary Safety Endpoint:**

[TODO: Company-specific -- Define primary safety endpoint, including adverse event definitions]

**Secondary Endpoints:**

[TODO: Company-specific -- Define secondary effectiveness and safety endpoints]

### 6.3 Sample Size and Power

**Proposed Sample Size:** [TODO]

**Power Analysis:**
- **Effect Size:** [TODO: Company-specific -- Clinically meaningful difference]
- **Alpha:** 0.05 (two-sided)
- **Power (1-beta):** 0.80 or higher
- **Statistical Test:** [TODO: Company-specific -- Superiority, non-inferiority, equivalence]
- **Dropout Rate Assumption:** [TODO]

[TODO: Company-specific -- Provide full sample size justification including assumptions, references, and sensitivity analyses]

### 6.4 Inclusion and Exclusion Criteria

**Inclusion Criteria:**
1. [TODO: Company-specific]
2. [TODO: Company-specific]
3. [TODO: Company-specific]

**Exclusion Criteria:**
1. [TODO: Company-specific]
2. [TODO: Company-specific]
3. [TODO: Company-specific]

### 6.5 Follow-Up Duration

[TODO: Company-specific -- Justify follow-up duration based on clinical outcomes and safety monitoring needs]

### 6.6 Statistical Analysis Plan

**Primary Analysis:** [TODO: Company-specific -- Intent-to-treat, per-protocol, or both]

**Interim Analysis:** [TODO: Company-specific -- Planned interim analyses, futility boundaries, and data monitoring committee role]

**Missing Data:** [TODO: Company-specific -- Approach for handling missing data, sensitivity analyses]

---

## 7. Benefit-Risk Assessment

### 7.1 Anticipated Benefits

[TODO: Company-specific -- Quantified clinical benefits based on nonclinical data and clinical rationale]

### 7.2 Known and Anticipated Risks

[TODO: Company-specific -- Device-related risks from risk analysis, procedure-related risks, and long-term risks]

### 7.3 Benefit-Risk Balance

[TODO: Company-specific -- Structured benefit-risk assessment following FDA's guidance framework]

### 7.4 Risk Mitigation Strategies

[TODO: Company-specific -- How identified risks will be mitigated through device design, labeling, training, or post-market surveillance]

---

## 8. Nonclinical Testing Summary

### 8.1 Biocompatibility

{biocompatibility_testing_plan}

**Standards:** ISO 10993-1:2009 (or latest edition)
**Endpoints:** {biocompat_endpoints_list}

[TODO: Company-specific -- Summarize completed biocompatibility testing results]

### 8.2 Performance Testing

{performance_testing_plan}

**Standards:** {performance_standards_list}

[TODO: Company-specific -- Bench testing results demonstrating device performance]

### 8.3 Animal Testing

[TODO: Company-specific -- Preclinical animal study results, including study design, endpoints, and key findings]

### 8.4 Electrical Safety and EMC

{electrical_testing_plan}

[TODO: Company-specific -- If applicable, electrical safety and EMC testing per IEC 60601]

### 8.5 Software Verification

{software_testing_plan}

[TODO: Company-specific -- If applicable, software V&V per IEC 62304]

---

## 9. Manufacturing and Quality

[TODO: Company-specific -- Overview of manufacturing process, GMP compliance, and quality system]

### 9.1 Manufacturing Overview

[TODO: Company-specific -- Manufacturing location, process description, critical manufacturing steps]

### 9.2 Quality System

[TODO: Company-specific -- Quality system overview, design control compliance, CAPA processes]

---

## 10. Regulatory Background

### 10.1 FDA Guidance Reviewed

We have reviewed the following FDA guidance documents:

- *Premarket Approval Application Decisions* (2022)
- *Design Considerations for Pivotal Clinical Investigations for Medical Devices* (2013)
- *Factors to Consider When Making Benefit-Risk Determinations* (2017)
- {additional_guidance_list}

### 10.2 Applicable Consensus Standards

{standards_list}

[TODO: Company-specific -- List of FDA-recognized consensus standards]

### 10.3 Safety Intelligence

{safety_intelligence_summary}

---

## 11. Post-Approval Considerations

### 11.1 Post-Approval Study Plan

[TODO: Company-specific -- Anticipated post-approval study requirements, conditions of approval]

### 11.2 Post-Market Surveillance Plan

[TODO: Company-specific -- Planned post-market surveillance strategy, including MDR reporting, periodic reports]

---

## 12. Meeting Logistics

### 12.1 Submission Timeline

- **Pre-Sub preparation target:** {presub_prep_date}
- **Pre-Sub submission to FDA:** {presub_submission_date}
- **FDA 75-day meeting deadline:** {fda_deadline_date}
- **Expected FDA feedback by:** {expected_feedback_date}
- **IDE submission target:** [TODO: Company-specific]
- **Clinical study initiation target:** [TODO: Company-specific]
- **Target PMA submission date:** {target_510k_date}

### 12.2 Preferred Meeting Format

**Requested format:** Teleconference or In-Person

**Proposed Duration:** 90 minutes

### 12.3 Expected Attendees

**From {applicant_name}:**
- [TODO: Company-specific -- Regulatory Affairs lead]
- [TODO: Company-specific -- Clinical Affairs lead]
- [TODO: Company-specific -- Biostatistician]
- [TODO: Company-specific -- Engineering/R&D lead]
- [TODO: Company-specific -- Principal Investigator (if identified)]

### 12.4 Proposed Agenda

1. **Introductions** (5 min)
2. **Device overview and clinical rationale** (15 min)
3. **Regulatory pathway confirmation** (5 min)
4. **Proposed clinical study design** (20 min)
5. **Endpoints and statistical approach** (15 min)
6. **Nonclinical testing sufficiency** (10 min)
7. **Benefit-risk framework** (10 min)
8. **FDA questions and feedback** (10 min)

---

## 13. Attachments

[TODO: Company-specific -- List all attachments included with this Pre-Sub]

1. Device photographs and illustrations
2. Nonclinical testing summary report
3. Draft clinical study protocol (if available)
4. Statistical analysis plan outline
5. Risk analysis summary (ISO 14971)
6. Benefit-risk assessment document
7. Investigator brochure (if available)
8. {additional_attachments}

---

## Disclaimer

> **Important:** This PMA Pre-Submission plan is AI-generated from public FDA data and project information. All content should be independently verified by qualified regulatory affairs professionals and clinical experts before submission to FDA. This document does not constitute regulatory or clinical advice.

---

**Document Control:**
- **Generated:** {generated_date}
- **Template:** pma_presub.md
- **Plugin Version:** 5.28.0
- **Project:** {project_name}
- **Meeting Type:** PMA Pre-Submission Meeting
- **Regulatory Pathway:** Premarket Approval (PMA)
